stockrow
Friday 6 November 2026
Export ZLAB’s income statement to Excel — free account
Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
25.40
2.80
+12.39%
Follow ZLAB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 4 | — |
| (22.56%) | (24.19%) | (26.91%) | (29.99%) | ||
| (14.89%) | (15.70%) | (16.81%) | (18.18%) | ||
ROIC |
(109.92%) | (132.39%) | (129.34%) | (21.32%) | |
Return on Tangible Assets |
(26.98%) | (29.74%) | (35.39%) | (40.80%) | |
Average Days of Receivables |
84.17 | 43.54 | 56.50 | 53.95 | |
Free Cash Flow per Share |
(1.50) | (1.20) | (1.45) | 0.00 | |
Free Cash Flow |
(164.13) | (132.76) | (162.43) | (196.89) | |
Capital Expenditures |
(13.34) | (31.76) | (29.05) | (37.68) | |
| Other line items | |||||
Cash ROIC |
(9.60%) | (8.11%) | (10.39%) | (24.14%) | |
Accounts Receivable Turnover |
4.81 | 6.94 | 5.69 | 5.86 | |
Accounts Payable Turnover |
1.58 | 1.66 | 1.60 | 0.00 | |
Inventory Turnover |
3.33 | 2.74 | 2.57 | 0.00 | |
Average Days of Payables |
270.50 | 241.40 | 254.93 | 0.00 | |
Days of Inventory on Hand |
142.78 | 164.47 | 169.51 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
48.01% | 49.81% | 52.69% | 54.06% | |
Selling, General and Administrative Expense of Revenue |
60.33% | 61.61% | 62.52% | 63.63% | |
Share Based Compensation of Revenue |
14.26% | 13.97% | 12.96% | 11.85% | |
Interest Coverage |
(44.05) | (42.85) | (44.13) | (45.16) | |
Operating CF/Net income |
0.86 | 0.57 | 0.71 | 0.80 | |
Depreciation/Fixed assets |
0.20 | 0.21 | 0.22 | 0.00 | |
Capex/Depreciation |
(1.38) | (3.15) | (2.79) | 0.00 | |
Revenue per Share |
4.20 | 4.09 | 4.03 | 0.00 | |
Operating CF per Share |
(1.38) | (0.91) | (1.19) | 0.00 | |
Capex per Share |
(0.12) | (0.29) | (0.26) | 0.00 | |
Capex to Sales |
0.03 | 0.07 | 0.06 | 0.09 |
Columns are period end dates · fundamentals updated 5 Nov 2026